| 1 | Falling through the cracks: what happens to survivors of preterm birth? | 2.5 | 6 | Citations (PDF) |
| 2 | Fractional exhaled nitric oxide in a respiratory healthy general population through the lifespan | 2.3 | 11 | Citations (PDF) |
| 3 | Heterogeneity of reduced FEV1 in early adulthood: A looking forward, looking backwards analysis | 4.0 | 11 | Citations (PDF) |
| 4 | Occluding mucous airway plugs in patients with obstructive lung diseases: a new treatable trait? | 2.5 | 3 | Citations (PDF) |
| 5 | Treatable Trait Guided Asthma Management: A Feasibility Study | 4.0 | 5 | Citations (PDF) |
| 6 | Prevalence, diagnostic accuracy, and healthcare utilization patterns in patients with COPD in primary healthcare: a population-based study | 3.9 | 10 | Citations (PDF) |
| 7 | Alteraciones espirométricas y sus factores de riesgo en la población joven ambulatoria | 0.8 | 0 | Citations (PDF) |
| 8 | Spirometric alterations and their risk factors in young ambulatory population | 0.1 | 0 | Citations (PDF) |
| 9 | Asthma and obstructive sleep apnea: A complex but treatable relationship | 8.7 | 2 | Citations (PDF) |
| 10 | Towards early detection and disease interception of COPD across the lifespan | 8.2 | 7 | Citations (PDF) |
| 11 | A person-centred clinical approach to the multimorbid patient with COPD | 2.7 | 16 | Citations (PDF) |
| 12 | Prevalence, Diagnostic Utility and Associated Characteristics of Bronchodilator Responsiveness | 8.9 | 38 | Citations (PDF) |
| 13 | From treatable traits to GETomics in airway disease: moving towards clinical practice | 8.2 | 19 | Citations (PDF) |
| 14 | Treatable Traits in Asthma: The Importance of Extrapulmonary Traits—GERD, CRSwNP, Atopic Dermatitis, and Depression/Anxiety | 3.3 | 34 | Citations (PDF) |
| 15 | Epigenome-Wide Association Studies of Chronic Obstructive Pulmonary Disease and Lung Function: A Systematic Review | 8.9 | 16 | Citations (PDF) |
| 16 | Early Life Exposures and the Development of Chronic Obstructive Pulmonary Disease across the Life Course | 8.9 | 21 | Citations (PDF) |
| 17 | Treatable traits in pre‐COPD: Time to extend the treatable traits paradigm beyond established disease | 4.0 | 24 | Citations (PDF) |
| 18 | Association of Preserved Ratio Impaired Spirometry with Arterial Stiffness | 3.4 | 10 | Citations (PDF) |
| 19 | Prevalence and etiotypes of persistent airflow obstruction in the general population across the lifetime | 2.6 | 1 | Citations (PDF) |
| 20 | Managing and discharging COPD patients hospitalized because of an exacerbation of respiratory symptoms: An opportunity to improve outcomes | 2.7 | 1 | Citations (PDF) |
| 21 | Lung function in young adults born small for gestational age at term | 4.0 | 6 | Citations (PDF) |
| 22 | Circulating Biomarkers in Young Individuals with Low Peak FEV1 | 8.9 | 12 | Citations (PDF) |
| 23 | Does arterial oxygenation during exercise add prognostic value in pulmonary arterial hypertension? | 2.6 | 3 | Citations (PDF) |
| 24 | Treatable Traits in Airway Disease: From Theory to Practice | 3.3 | 80 | Citations (PDF) |
| 25 | Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary | 4.0 | 32 | Citations (PDF) |
| 26 | Persistence of a SARS-CoV-2 T-cell response in patients with long COVID and lung sequelae after COVID-19 | 2.5 | 6 | Citations (PDF) |
| 27 | Clinical characteristics of chronic obstructive pulmonary disease in never-smokers: A systematic review | 2.6 | 16 | Citations (PDF) |
| 28 | Cluster Analyses From the Real-World NOVELTY Study: Six Clusters Across the Asthma-COPD Spectrum | 3.3 | 10 | Citations (PDF) |
| 29 | When GETomics meets aging and exercise in COPD | 2.6 | 17 | Citations (PDF) |
| 30 | GOLD 2023 Executive Summary: responses from the GOLD Scientific Committee | 8.7 | 16 | Citations (PDF) |
| 31 | GOLD COPD DOCUMENT 2023: a brief update for practicing cardiologists | 2.8 | 45 | Citations (PDF) |
| 32 | Supranormal lung function: Prevalence, associated factors and clinical manifestations across the lifespan | 4.0 | 15 | Citations (PDF) |
| 33 | Updated Definition of Chronic Obstructive Pulmonary Disease in the Global Initiative for Chronic Obstructive Lung Disease 2023 Executive Report: Expert Perspectives | 0.2 | 0 | Citations (PDF) |
| 34 | Phenotypes, Etiotypes, and Endotypes of Exacerbations of Chronic Obstructive Pulmonary Disease | 8.9 | 75 | Citations (PDF) |
| 35 | Iron accumulation drives fibrosis, senescence and the senescence-associated secretory phenotype | 17.1 | 192 | Citations (PDF) |
| 36 | A New and More Sensitive Method to Integrate the Desaturation Distance Ratio During a 6-Minute Walking Test in Chronic Respiratory Diseases: Physiological Correlates | 1.4 | 6 | Citations (PDF) |
| 37 | Specific miRNA Profile in Chronic Obstructive Pulmonary Disease Related to Biomass Smoke Exposure | 1.4 | 3 | Citations (PDF) |
| 38 | Single inhaler triple therapy (SITT) in asthma: Systematic review and practice implications | 6.7 | 51 | Citations (PDF) |
| 39 | Treatment Trials in Young Patients with Chronic Obstructive Pulmonary Disease and Pre–Chronic Obstructive Pulmonary Disease Patients: Time to Move Forward | 8.9 | 161 | Citations (PDF) |
| 40 | ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations | 8.7 | 59 | Citations (PDF) |
| 41 | Changes in lung function in European adults born between 1884 and 1996 and implications for the diagnosis of lung disease: a cross-sectional analysis of ten population-based studies | 23.3 | 31 | Citations (PDF) |
| 42 | The 7 Cardinal Sins of COPD in Spain | 1.4 | 5 | Citations (PDF) |
| 43 | Severe Pulmonary Hypertension in COPDChest, 2022, 162, 202-212 | 1.0 | 106 | Citations (PDF) |
| 44 | Distribution of chronic cough phenotypes in the general population: A cross-sectional analysis of the LEAD cohort in Austria | 2.6 | 28 | Citations (PDF) |
| 45 | Add-on inhaled budesonide in the treatment of hospitalised patients with COVID-19: a randomised clinical trial | 8.7 | 17 | Citations (PDF) |
| 46 | Predicting Early Hospital Readmissions in COPD Patients Using an Electronic Nose | 1.4 | 1 | Citations (PDF) |
| 47 | Elevated plasma levels of epithelial and endothelial cell markers in COVID-19 survivors with reduced lung diffusing capacity six months after hospital discharge | 4.2 | 42 | Citations (PDF) |
| 48 | Más alla del binomio EPOC-tabaco: nuevas oportunidades para la prevención y tratamiento precoz de la enfermedad | 0.8 | 6 | Citations (PDF) |
| 49 | [Translated article] Histology Study of Postmortem Lung Biopsies in Patients With Covid-19 Pneumonia | 1.4 | 1 | Citations (PDF) |
| 50 | Pathogenesis of chronic obstructive pulmonary disease: understanding the contributions of gene–environment interactions across the lifespan | 23.3 | 295 | Citations (PDF) |
| 51 | Real-life burden of hospitalisations due to COPD exacerbations in Spain | 2.5 | 13 | Citations (PDF) |
| 52 | Chronic Bronchial Infection Is Associated with More Rapid Lung Function Decline in Chronic Obstructive Pulmonary Disease | 3.4 | 34 | Citations (PDF) |
| 53 | Blood Eosinophils and Chronic Obstructive Pulmonary Disease: A Global Initiative for Chronic Obstructive Lung Disease Science Committee 2022 Review | 8.9 | 148 | Citations (PDF) |
| 54 | Beyond the COPD-tobacco binomium: New opportunities for the prevention and early treatment of the disease | 0.1 | 1 | Citations (PDF) |
| 55 | Treatable traits in the NOVELTY study | 4.0 | 73 | Citations (PDF) |
| 56 | Contemporary Challenges in the Management of Asthma and Chronic Obstructive Pulmonary Disease: Expert Perspectives on Optimising Outcomes Through Guidelines Implementation, Inhaler Selection, and Patient Engagement | 0.1 | 0 | Citations (PDF) |
| 57 | Inhaled corticosteroids for the treatment of COVID-19 | 8.2 | 15 | Citations (PDF) |
| 58 | New Frontiers in Chronic Obstructive Pulmonary Disease: Where Are We Heading? | 0.1 | 1 | Citations (PDF) |
| 59 | Bronchial Infection and Temporal Evolution of Bronchiectasis in Patients With Chronic Obstructive Pulmonary Disease | 5.2 | 49 | Citations (PDF) |
| 60 | Treatable Traits That Predict Health Status and Treatment Response in Airway Disease | 3.3 | 53 | Citations (PDF) |
| 61 | Lack of Bacterial Colonization Measure in Randomized Controlled Trial on Inhaled Corticosteroids Effect in Patients with Chronic Obstructive Pulmonary Disease | 8.9 | 0 | Citations (PDF) |
| 62 | From GOLD 0 to Pre-COPD | 8.9 | 257 | Citations (PDF) |
| 63 | Lung DNA Methylation in Chronic Obstructive Pulmonary Disease: Relationship with Smoking Status and Airflow Limitation Severity | 8.9 | 28 | Citations (PDF) |
| 64 | Liver epigenome changes in patients with hepatopulmonary syndrome: A pilot study | 2.3 | 4 | Citations (PDF) |
| 65 | Heterogeneity within and between physician-diagnosed asthma and/or COPD: NOVELTY cohort | 8.7 | 75 | Citations (PDF) |
| 66 | Low birth weight as a potential risk factor for severe COVID-19 in adults | 3.4 | 13 | Citations (PDF) |
| 67 | Improving lung health in low-income and middle-income countries: from challenges to solutions | 62.1 | 417 | Citations (PDF) |
| 68 | Lung Function sequelae in COVID-19 Patients 3 Months After Hospital Discharge | 1.4 | 38 | Citations (PDF) |
| 69 | Risk Factors and Relation with Mortality of a New Acquisition and Persistence of
Pseudomonas aeruginosa
in COPD Patients | 2.0 | 27 | Citations (PDF) |
| 70 | Chronic bronchial infection and incident cardiovascular events in chronic obstructive pulmonary disease patients: A long‐term observational study | 4.0 | 15 | Citations (PDF) |
| 71 | Cellular Senescence in Lung Fibrosis | 4.4 | 71 | Citations (PDF) |
| 72 | Lung function trajectory and biomarkers in the Tasmanian Longitudinal Health Study | 2.5 | 24 | Citations (PDF) |
| 73 | Spirometry: A practical lifespan predictor of global health and chronic respiratory and non-respiratory diseases | 2.7 | 57 | Citations (PDF) |
| 74 | Informe de la Barcelona-Boston Lung Conference 2021 | 0.8 | 0 | Citations (PDF) |
| 75 | Lung Function Levels Influence the Association between Obesity and Risk of COVID-19 | 8.9 | 4 | Citations (PDF) |
| 76 | COVID-19 diagnostic tests: Importance of the clinical context | 0.1 | 8 | Citations (PDF) |
| 77 | Pruebas diagnósticas COVID-19: importancia del contexto clínico | 0.8 | 7 | Citations (PDF) |
| 78 | Is asthma associated with COVID-19 infection? A UK Biobank analysis | 2.5 | 10 | Citations (PDF) |
| 79 | Moving towards a Treatable Traits model of care for the management of obstructive airways diseases | 2.6 | 54 | Citations (PDF) |
| 80 | Markers of disease activity in COPD: an 8-year mortality study in the ECLIPSE cohort | 8.7 | 44 | Citations (PDF) |
| 81 | Estudio histológico mediante biopsia pulmonar post mortem en pacientes con neumonía por COVID-19 | 1.4 | 1 | Citations (PDF) |
| 82 | Effect of a Pulmonary Embolism Diagnostic Strategy on Clinical Outcomes in Patients Hospitalized for COPD Exacerbation | 16.5 | 52 | Citations (PDF) |
| 83 | Telomere Length but Not Mitochondrial DNA Copy Number Is Altered in Both Young and Old COPD | 2.4 | 11 | Citations (PDF) |
| 84 | Predicting response to benralizumab in chronic obstructive pulmonary disease: analyses of GALATHEA and TERRANOVA studies | 23.3 | 116 | Citations (PDF) |
| 85 | Clinical Fingerprinting: A Way to Address the Complexity and Heterogeneity of Bronchiectasis in Practice | 8.9 | 17 | Citations (PDF) |
| 86 | An imported case of e-cigarette or vaping associated lung injury in Barcelona | 8.7 | 27 | Citations (PDF) |
| 87 | Chronic Obstructive Pulmonary Disease Pathogenesis | 3.4 | 10 | Citations (PDF) |
| 88 | Phenotypic characterisation of early COPD: a prospective case–control study | 2.5 | 37 | Citations (PDF) |
| 89 | Withdrawal of inhaled corticosteroids in COPD | 8.7 | 1 | Citations (PDF) |
| 90 | Amerindian Ancestry Influences Genetic Susceptibility to Chronic Obstructive Pulmonary Disease | 2.4 | 10 | Citations (PDF) |
| 91 | Outcomes and cost of lung cancer patients treated surgically or medically in Catalunya: cost–benefit implications for lung cancer screening programs | 2.0 | 11 | Citations (PDF) |
| 92 | Smaller Left Ventricle Size at Noncontrast CT Is Associated with Lower Mortality in COPDGene Participants | 8.7 | 10 | Citations (PDF) |
| 93 | Report of the Barcelona Boston Lung Conference 2020 | 0.8 | 0 | Citations (PDF) |
| 94 | Blood eosinophil count in the general population: typical values and potential confounders | 8.7 | 167 | Citations (PDF) |
| 95 | Inhaled Steroids, Circulating Eosinophils, Chronic Airway Infection, and Pneumonia Risk in Chronic Obstructive Pulmonary Disease. A Network Analysis | 8.9 | 101 | Citations (PDF) |
| 96 | Factors Associated with Low Lung Function in Different Age Bins in the General Population | 8.9 | 50 | Citations (PDF) |
| 97 | Reduced airway levels of fatty-acid binding protein 4 in COPD: relationship with airway infection and disease severity | 4.2 | 17 | Citations (PDF) |
| 98 | Acute exacerbations of idiopathic pulmonary fibrosis: Does clinical stratification or steroid treatment matter? | 1.7 | 21 | Citations (PDF) |
| 99 | UPSTAGING, CENTRALITY AND SURVIVAL IN EARLY STAGE NON-SMALL CELL LUNG CANCER VIDEO-ASSISTED SURGERY | 2.6 | 25 | Citations (PDF) |
| 100 | Las bronquiectasias: una enfermedad compleja y heterogénea | 1.4 | 18 | Citations (PDF) |
| 101 | Multi-level immune response network in mild-moderate Chronic Obstructive Pulmonary Disease (COPD) | 4.2 | 43 | Citations (PDF) |
| 102 | Bronchiectasis: A Complex, Heterogeneous Disease | 1.4 | 10 | Citations (PDF) |
| 103 | EARLY COPD: determinantes de la aparición y progresión de la enfermedad pulmonar obstructiva crónica en adultos jóvenes. Protocolo de un estudio caso-control con seguimiento | 1.4 | 11 | Citations (PDF) |
| 104 | Increased rate of FEV1 decline in HIV patients despite effective treatment with HAART | 2.3 | 7 | Citations (PDF) |
| 105 | Update on the Pathogenesis of Chronic Obstructive Pulmonary Disease | 34.5 | 507 | Citations (PDF) |
| 106 | The BIOMEPOC Project: Personalized Biomarkers and Clinical Profiles in Chronic Obstructive Pulmonary Disease | 1.4 | 8 | Citations (PDF) |
| 107 | Heterogeneidad y complejidad del síndrome bronquiectasias: un reto pendiente | 1.4 | 12 | Citations (PDF) |
| 108 | Prospective observational study in patients with obstructive lung disease: NOVELTY design | 2.5 | 49 | Citations (PDF) |
| 109 | The rationale, design, and methods of a randomized, controlled trial to evaluate the efficacy and safety of an active strategy for the diagnosis and treatment of acute pulmonary embolism during exacerbations of chronic obstructive pulmonary disease | 2.0 | 11 | Citations (PDF) |
| 110 | Determinants of the Appearance and Progression of Early-Onset Chronic Obstructive Pulmonary Disease in Young Adults. A Case–Control Study With Follow-Up | 1.4 | 6 | Citations (PDF) |
| 111 | Relationship between the respiratory microbiome and the severity of airflow limitation, history of exacerbations and circulating eosinophils in COPD patients | 2.4 | 53 | Citations (PDF) |
| 112 | Benralizumab for the Prevention of COPD Exacerbations | 34.5 | 334 | Citations (PDF) |
| 113 | Precision medicine in obstructive sleep apnoea | 23.3 | 122 | Citations (PDF) |
| 114 | Smoking Impairs the Immunomodulatory Capacity of Lung-Resident Mesenchymal Stem Cells in Chronic Obstructive Pulmonary Disease | 3.8 | 26 | Citations (PDF) |
| 115 | Treatable traits: a new paradigm for 21st century management of chronic airway diseases: Treatable Traits Down Under International Workshop report | 8.7 | 292 | Citations (PDF) |
| 116 | Physical Activity Is Associated with Attenuated Disease Progression in Chronic Obstructive Pulmonary Disease | 0.8 | 51 | Citations (PDF) |
| 117 | Heterogeneity and Complexity in Bronchiectasis: A Pending Challenge | 1.4 | 2 | Citations (PDF) |
| 118 | Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019 | 8.7 | 1,645 | Citations (PDF) |
| 119 | Lecciones de una vida: Conferencia Manuel Tapia 2018 | 1.4 | 0 | Citations (PDF) |
| 120 | Arterial Vascular Pruning, Right Ventricular Size, and Clinical Outcomes in Chronic Obstructive Pulmonary Disease. A Longitudinal Observational Study | 8.9 | 120 | Citations (PDF) |
| 121 | Lung function trajectories in health and disease | 23.3 | 331 | Citations (PDF) |
| 122 | Chronic obstructive pulmonary disease at the beginning of the XXI Century | 1.2 | 1 | Citations (PDF) |
| 123 | Early Life Origins of Asthma: A Review of Potential Effectors | 1.5 | 36 | Citations (PDF) |
| 124 | Current Controversies in Chronic Obstructive Pulmonary Disease. A Report from the Global Initiative for Chronic Obstructive Lung Disease Scientific Committee | 3.4 | 17 | Citations (PDF) |
| 125 | Proyecto de biomarcadores y perfiles clínicos personalizados en la enfermedad pulmonar obstructiva crónica (proyecto BIOMEPOC) | 1.4 | 25 | Citations (PDF) |
| 126 | Do sputum or circulating blood samples reflect the pulmonary transcriptomic differences of COPD patients? A multi-tissue transcriptomic network META-analysis | 4.2 | 13 | Citations (PDF) |
| 127 | The LEAD (Lung, Heart, Social, Body) Study: Objectives, Methodology, and External Validity of the Population-Based Cohort Study | 1.8 | 60 | Citations (PDF) |
| 128 | From systems biology to P4 medicine: applications in respiratory medicine | 8.2 | 42 | Citations (PDF) |
| 129 | COPD: time to improve its taxonomy? | 2.5 | 100 | Citations (PDF) |
| 130 | Emphysema and extrapulmonary tissue loss in COPD: a multi-organ loss of tissue phenotype | 8.7 | 83 | Citations (PDF) |
| 131 | Hospitalizations due to exacerbations of COPD: A big data perspective | 2.6 | 25 | Citations (PDF) |
| 132 | Persistently elevated exhaled nitric oxide fraction is associated with increased risk of exacerbation in COPD | 8.7 | 73 | Citations (PDF) |
| 133 | Cardiovascular Disease Does Not Predict Exacerbation Rate or Mortality in Chronic Obstructive Pulmonary Disease | 8.9 | 10 | Citations (PDF) |
| 134 | Spirometrically Confirmed Chronic Obstructive Pulmonary Disease Worsens Long-Term Prognosis after Percutaneous Coronary Intervention | 8.9 | 9 | Citations (PDF) |
| 135 | After asthma: redefining airways diseases | 62.1 | 984 | Citations (PDF) |
| 136 | Pulmonary function predicts mortality and hospitalizations in outpatients with heart failure and preserved ejection fraction | 2.6 | 15 | Citations (PDF) |
| 137 | Expert Panel Discusses the Importance of Systems Medicine | 0.7 | 1 | Citations (PDF) |
| 138 | Inhaled corticosteroids in COPD: friend or foe? | 8.7 | 217 | Citations (PDF) |
| 139 | Whole exome sequencing analysis in severe chronic obstructive pulmonary disease | 2.9 | 35 | Citations (PDF) |
| 140 | Characterization, localization and comparison of c-Kit+ lung cells in never smokers and smokers with and without COPD | 2.4 | 6 | Citations (PDF) |
| 141 | The dyspnoea–inactivity vicious circle in COPD: development and external validation of a conceptual model | 8.7 | 146 | Citations (PDF) |
| 142 | Circulating eosinophil levels do not predict severe exacerbations in COPD: a retrospective study | 2.5 | 25 | Citations (PDF) |
| 143 | How to Define Early Chronic Obstructive Pulmonary Disease | 8.9 | 9 | Citations (PDF) |
| 144 | Pulmonary Vascular Involvement in Chronic Obstructive Pulmonary Disease. Is There a Pulmonary Vascular Phenotype? | 8.9 | 185 | Citations (PDF) |
| 145 | Comparative analysis of COPD associated with tobacco smoking, biomass smoke exposure or both | 4.2 | 53 | Citations (PDF) |
| 146 | Distribution, temporal stability and association with all-cause mortality of the 2017 GOLD groups in the ECLIPSE cohort | 2.6 | 15 | Citations (PDF) |
| 147 | Estudio de la validez de las versiones en catalán, gallego y vasco del cuestionario COPD assessment test y equivalencia con la versión en castellano | 1.4 | 4 | Citations (PDF) |
| 148 | Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Lung Disease 2017 Report | 4.0 | 324 | Citations (PDF) |
| 149 | Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary | 8.7 | 617 | Citations (PDF) |
| 150 | Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary | 8.9 | 2,817 | Citations (PDF) |
| 151 | Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary | 1.4 | 188 | Citations (PDF) |
| 152 | Different dyspnoea perception in COPD patients with frequent and infrequent exacerbations | 5.6 | 61 | Citations (PDF) |
| 153 | Genetic Association and Risk Scores in a Chronic Obstructive Pulmonary Disease Meta-analysis of 16,707 Subjects | 3.8 | 65 | Citations (PDF) |
| 154 | The microbiome in respiratory medicine: current challenges and future perspectives | 8.7 | 233 | Citations (PDF) |
| 155 | The Intersection of Aging Biology and the Pathobiology of Lung Diseases: A Joint NHLBI/NIA Workshop | 3.4 | 67 | Citations (PDF) |
| 156 | Validity Study of Catalan, Galician and Basque Language Versions of the COPD Assessment Test and Equivalence With the Spanish Version | 1.4 | 1 | Citations (PDF) |
| 157 | Do COPD subtypes really exist? COPD heterogeneity and clustering in 10 independent cohorts | 5.6 | 90 | Citations (PDF) |
| 158 | Predicting the future from the past: volatile markers for respiratory infections | 8.7 | 1 | Citations (PDF) |
| 159 | Informe 2017 de la Iniciativa Global para el Diagnóstico, Tratamiento y Prevención de la Enfermedad Pulmonar Obstructiva Crónica: Resumen Ejecutivo de GOLD | 1.4 | 336 | Citations (PDF) |
| 160 | Body mass index change in gastrointestinal cancer and chronic obstructive pulmonary disease is associated with Dedicator of Cytokinesis 1 | 9.1 | 14 | Citations (PDF) |
| 161 | Multi-level differential network analysis of COPD exacerbations | 8.7 | 44 | Citations (PDF) |
| 162 | Precision medicine in airway diseases: moving to clinical practice | 8.7 | 204 | Citations (PDF) |
| 163 | What does endotyping mean for treatment in chronic obstructive pulmonary disease? | 62.1 | 92 | Citations (PDF) |
| 164 | Blood eosinophil count and exacerbation risk in patients with COPD | 8.7 | 75 | Citations (PDF) |
| 165 | Towards a global initiative for fibrosis treatment (GIFT) | 2.5 | 8 | Citations (PDF) |
| 166 | Redefining Cut-Points for High Symptom Burden of the Global Initiative for Chronic Obstructive Lung Disease Classification in 18,577 Patients With Chronic Obstructive Pulmonary Disease | 2.4 | 45 | Citations (PDF) |
| 167 | Lung function in early adulthood and health in later life: a transgenerational cohort analysis | 23.3 | 332 | Citations (PDF) |
| 168 | Sex-Based Genetic Association Study Identifies
CELSR1
as a Possible Chronic Obstructive Pulmonary Disease Risk Locus among Women | 3.8 | 32 | Citations (PDF) |
| 169 | Natural history of COPD: gaps and opportunities | 2.5 | 48 | Citations (PDF) |
| 170 | The EASI model: A first integrative computational approximation to the natural history of COPD | 2.3 | 4 | Citations (PDF) |
| 171 | Inspiratory capacity‐to‐total lung capacity ratio and dyspnoea predict exercise capacity decline in COPD | 4.0 | 20 | Citations (PDF) |
| 172 | Multilevel, Dynamic Chronic Obstructive Pulmonary Disease Heterogeneity. A Challenge for Personalized Medicine | 3.4 | 25 | Citations (PDF) |
| 173 | Ausencia de correlación entre marcadores de inflamación pulmonar y sistémica en pacientes con enfermedad pulmonar obstructiva crónica: un análisis bi-compartimental simultáneo | 1.4 | 17 | Citations (PDF) |
| 174 | Oral Low-dose Theophylline on Top of Inhaled Fluticasone-Salmeterol Does Not Reduce Exacerbations in Patients With Severe COPDChest, 2016, 150, 123-130 | 1.0 | 56 | Citations (PDF) |
| 175 | Effect of Aclidinium Bromide on Exacerbations in Patients with Moderate-to-Severe COPD: A Pooled Analysis of Five Phase III, Randomized, Placebo-Controlled Studies | 2.0 | 9 | Citations (PDF) |
| 176 | The inflammasome pathway in stable COPD and acute exacerbations | 2.5 | 64 | Citations (PDF) |
| 177 | Chronic Obstructive Pulmonary Disease and Cardiac Diseases. An Urgent Need for Integrated Care | 8.9 | 217 | Citations (PDF) |
| 178 | Determinants of exercise-induced oxygen desaturation including pulmonary emphysema in COPD: Results from the ECLIPSE study | 2.6 | 34 | Citations (PDF) |
| 179 | Biomarkers, the control panel and personalized COPD medicine | 4.0 | 44 | Citations (PDF) |
| 180 | Current Controversies in the Pharmacological Treatment of Chronic Obstructive Pulmonary Disease | 8.9 | 77 | Citations (PDF) |
| 181 | Lack of Correlation Between Pulmonary and Systemic Inflammation Markers in Patients with Chronic Obstructive Pulmonary Disease: A Simultaneous, Two-Compartmental Analysis | 1.4 | 14 | Citations (PDF) |
| 182 | Exome Array Analysis Identifies a Common Variant in
IL27
Associated with Chronic Obstructive Pulmonary Disease | 8.9 | 55 | Citations (PDF) |
| 183 | A comparison of COPD patients with and without ACOS in the ECLIPSE study | 8.7 | 43 | Citations (PDF) |
| 184 | Effects of simvastatin in chronic obstructive pulmonary disease: Results of a pilot, randomized, placebo-controlled clinical trial | 1.2 | 16 | Citations (PDF) |
| 185 | Circulating desmosine levels do not predict emphysema progression but are associated with cardiovascular risk and mortality in COPD | 8.7 | 79 | Citations (PDF) |
| 186 | Treatable traits: toward precision medicine of chronic airway diseases | 8.7 | 991 | Citations (PDF) |
| 187 | Network Analysis of Lung Transcriptomics Reveals a Distinct B-Cell Signature in Emphysema | 8.9 | 133 | Citations (PDF) |
| 188 | Assessment of a Combined Panel of Six Serum Tumor Markers for Lung Cancer | 8.9 | 173 | Citations (PDF) |
| 189 | Haemophilus influenzae induces steroid-resistant inflammatory responses in COPD | 2.4 | 22 | Citations (PDF) |
| 190 | Using the Electronic Nose to Identify Airway Infection during COPD Exacerbations | 2.3 | 75 | Citations (PDF) |
| 191 | Ventilation/Perfusion Distribution Abnormalities In Morbidly Obese Subjects Before and After Bariatric SurgeryChest, 2015, 147, 1127-1134 | 1.0 | 59 | Citations (PDF) |
| 192 | Blood Eosinophils: A Biomarker of Response to Extrafine Beclomethasone/Formoterol in Chronic Obstructive Pulmonary Disease | 8.9 | 391 | Citations (PDF) |
| 193 | B Cell–Activating Factor. An Orchestrator of Lymphoid Follicles in Severe Chronic Obstructive Pulmonary Disease | 8.9 | 118 | Citations (PDF) |
| 194 | Chronic obstructive pulmonary disease: The golden decade. Implications for the diagnosis, prevention and treatment of chronic obstructive pulmonary disease | 0.1 | 1 | Citations (PDF) |
| 195 | Personalized Respiratory Medicine: Exploring the Horizon, Addressing the Issues. Summary of a BRN-AJRCCM Workshop Held in Barcelona on June 12, 2014 | 8.9 | 65 | Citations (PDF) |
| 196 | Identification of Five Chronic Obstructive Pulmonary Disease Subgroups with Different Prognoses in the ECLIPSE Cohort Using Cluster Analysis | 3.4 | 142 | Citations (PDF) |
| 197 | Benefits of physical activity on COPD hospitalisation depend on intensity | 8.7 | 83 | Citations (PDF) |
| 198 | Molecular and clinical diseasome of comorbidities in exacerbated COPD patients | 8.7 | 37 | Citations (PDF) |
| 199 | The asthma–COPD overlap syndrome: towards a revised taxonomy of chronic airways diseases? | 23.3 | 157 | Citations (PDF) |
| 200 | Circulating Soluble Receptor for Advanced Glycation End Products (sRAGE) as a Biomarker of Emphysema and the RAGE Axis in the Lung | 8.9 | 97 | Citations (PDF) |
| 201 | Clinical and prognostic heterogeneity of C and D GOLD groups | 8.7 | 11 | Citations (PDF) |
| 202 | Lung-Function Trajectories Leading to Chronic Obstructive Pulmonary Disease | 34.5 | 1,228 | Citations (PDF) |
| 203 | Assessment of health status and program performance in patients on long-term oxygen therapy | 2.6 | 23 | Citations (PDF) |
| 204 | Current concepts in targeting chronic obstructive pulmonary disease pharmacotherapy: making progress towards personalised management | 62.1 | 231 | Citations (PDF) |
| 205 | Characterisation and prognosis of undiagnosed chronic obstructive pulmonary disease patients at their first hospitalisation | 2.4 | 23 | Citations (PDF) |
| 206 | One-year change in health status and subsequent outcomes in COPD | 5.6 | 52 | Citations (PDF) |
| 207 | Hospitalized Exacerbations of COPDChest, 2015, 147, 999-1007 | 1.0 | 307 | Citations (PDF) |
| 208 | Salmeterol/fluticasone combination instead of indacaterol orvice-versa? | 8.7 | 1 | Citations (PDF) |
| 209 | An official American Thoracic Society/European Respiratory Society statement: research questions in COPD | 8.7 | 146 | Citations (PDF) |
| 210 | Lung-Function Trajectories and Chronic Obstructive Pulmonary Disease | 34.5 | 26 | Citations (PDF) |
| 211 | Expansion of myeloid-derived suppressor cells in chronic obstructive pulmonary disease and lung cancer: potential link between inflammation and cancer | 4.6 | 35 | Citations (PDF) |
| 212 | Prognostic value of variables derived from the six-minute walk test in patients with COPD: Results from the ECLIPSE study | 2.6 | 101 | Citations (PDF) |
| 213 | Continuous fat-free mass decline in COPD: fact or fiction? | 8.7 | 14 | Citations (PDF) |
| 214 | Enfermedad pulmonar obstructiva crónica: la década prodigiosa. Implicaciones para su diagnóstico, prevención y tratamiento | 0.8 | 4 | Citations (PDF) |
| 215 | Critical assessment of the current guidelines for the management and treatment of morbidly obese patients | 2.8 | 30 | Citations (PDF) |
| 216 | Systemic Inflammatory Response to Smoking in Chronic Obstructive Pulmonary Disease: Evidence of a Gender Effect | 2.3 | 46 | Citations (PDF) |
| 217 | The Systemic Inflammome of Severe Obesity before and after Bariatric Surgery | 2.3 | 51 | Citations (PDF) |
| 218 | Fibrinogen and COPD: Now what? | 0.7 | 17 | Citations (PDF) |
| 219 | Prevention of Exacerbations in Chronic Obstructive Pulmonary Disease: Knowns and Unknowns | 0.7 | 26 | Citations (PDF) |
| 220 | A diVIsive Shuffling Approach (VIStA) for gene expression analysis to identify subtypes in Chronic Obstructive Pulmonary Disease | 3.1 | 24 | Citations (PDF) |
| 221 | Network Analysis in the Investigation of Chronic Respiratory Diseases. From Basics to Application | 8.9 | 45 | Citations (PDF) |
| 222 | Eosinophilic inflammation in COPD: prevalence and clinical characteristics | 8.7 | 469 | Citations (PDF) |
| 223 | Air pollution and biomarkers of systemic inflammation and tissue repair in COPD patients | 8.7 | 110 | Citations (PDF) |
| 224 | Inhaled corticosteroids and systemic inflammatory response in community‐acquired pneumonia: A prospective clinical study | 4.0 | 20 | Citations (PDF) |
| 225 | Prevalence of and risk factors for pulmonary abnormalities in HIV‐infected patients treated with antiretroviral therapy | 2.8 | 68 | Citations (PDF) |
| 226 | Common Genetic Variants Associated with Resting Oxygenation in Chronic Obstructive Pulmonary Disease | 3.8 | 19 | Citations (PDF) |
| 227 | Network medicine analysis of COPD multimorbidities | 4.2 | 51 | Citations (PDF) |
| 228 | An inter-rater reliability study of the prescribing indicated medications quality indicators of the Assessing Care Of Vulnerable Elders (ACOVE) 3 criteria as a potentially inappropriate prescribing tool | 3.4 | 13 | Citations (PDF) |
| 229 | Biomarkers in COPD | 3.4 | 53 | Citations (PDF) |
| 230 | Coronary artery calcification is increased in patients with COPD and associated with increased morbidity and mortality | 5.6 | 195 | Citations (PDF) |
| 231 | Moving from the Oslerian paradigm to the post-genomic era: are asthma and COPD outdated terms? | 5.6 | 68 | Citations (PDF) |
| 232 | Persistent systemic inflammation and symptoms of depression among patients with COPD in the ECLIPSE cohort | 2.6 | 26 | Citations (PDF) |
| 233 | Identification of airway bacterial colonization by an electronic nose in Chronic Obstructive Pulmonary Disease | 2.6 | 63 | Citations (PDF) |
| 234 | A comparison of the efficacy and safety of once-daily fluticasone furoate/vilanterol with twice-daily fluticasone propionate/salmeterol in moderate to very severe COPD | 8.7 | 54 | Citations (PDF) |
| 235 | Characterisation and impact of reported and unreported exacerbations: results from ATTAIN | 8.7 | 74 | Citations (PDF) |
| 236 | Structure–function relationship in COPD revisited: an in vivo microscopy view | 5.6 | 10 | Citations (PDF) |
| 237 | The path to personalised medicine in COPD | 5.6 | 174 | Citations (PDF) |
| 238 | Lung Function Abnormalities are Highly Frequent in Patients with Heart Failure and Preserved Ejection Fraction | 0.9 | 44 | Citations (PDF) |
| 239 | Quantitative Computed Tomography Measures of Pectoralis Muscle Area and Disease Severity in Chronic Obstructive Pulmonary Disease. A Cross-Sectional Study | 3.4 | 232 | Citations (PDF) |
| 240 | Lessons from ECLIPSE: a review of COPD biomarkers | 5.6 | 142 | Citations (PDF) |
| 241 | Hospital admissions and exercise capacity decline in patients with COPD | 8.7 | 41 | Citations (PDF) |
| 242 | Extrafine beclomethasone/formoterol in severe COPD patients with history of exacerbations | 2.6 | 105 | Citations (PDF) |
| 243 | Should We View Chronic Obstructive Pulmonary Disease Differently after ECLIPSE?. A Clinical Perspective from the Study Team | 8.9 | 140 | Citations (PDF) |
| 244 | Chronic Obstructive Pulmonary Disease heterogeneity: challenges for health risk assessment, stratification and management | 6.4 | 37 | Citations (PDF) |
| 245 | Prevention of Exacerbations in Chronic Obstructive Pulmonary Disease: Knowns and Unknowns | 0.7 | 0 | Citations (PDF) |
| 246 | A randomised trial of fluticasone furoate/vilanterol (50/25 μg; 100/25 μg) on lung function in COPD | 2.6 | 89 | Citations (PDF) |
| 247 | Systemic Soluble Receptor for Advanced Glycation Endproducts Is a Biomarker of Emphysema and Associated with AGER Genetic Variants in Patients with Chronic Obstructive Pulmonary Disease | 8.9 | 151 | Citations (PDF) |
| 248 | Cardiovascular Comorbidity in COPDChest, 2013, 144, 1163-1178 | 1.0 | 336 | Citations (PDF) |
| 249 | Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort | 2.6 | 398 | Citations (PDF) |
| 250 | Pathophysiology of muscle dysfunction in COPD | 2.8 | 204 | Citations (PDF) |
| 251 | Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease | 8.9 | 7,127 | Citations (PDF) |
| 252 | Prescription of inhalers in asthma and COPD: Towards a rational, rapid and effective approach | 2.6 | 92 | Citations (PDF) |
| 253 | Differential effects of smoking and COPD upon circulating myeloid derived suppressor cells | 2.6 | 31 | Citations (PDF) |
| 254 | The presence and progression of emphysema in COPD as determined by CT scanning and biomarker expression: a prospective analysis from the ECLIPSE study | 23.3 | 256 | Citations (PDF) |
| 255 | Six-Minute-Walk Test in Chronic Obstructive Pulmonary Disease | 8.9 | 312 | Citations (PDF) |
| 256 | FAQs about the GOLD 2011 assessment proposal of COPD: a comparative analysis of four different cohorts | 8.7 | 90 | Citations (PDF) |
| 257 | Lungs, Bone Marrow, and Adipose Tissue. A Network Approach to the Pathobiology of Chronic Obstructive Pulmonary Disease | 8.9 | 34 | Citations (PDF) |
| 258 | The COPD control panel: towards personalised medicine in COPD | 5.6 | 107 | Citations (PDF) |
| 259 | Authors response. The chronic obstructive pulmonary disease (COPD) control panel: towards personalised medicine in COPD | 5.6 | 0 | Citations (PDF) |
| 260 | Phenotypes and Disease Characterization in Chronic Obstructive Pulmonary Disease. Toward the Extinction of Phenotypes? | 3.4 | 44 | Citations (PDF) |
| 261 | HLA Distribution in COPD Patients | 2.0 | 18 | Citations (PDF) |
| 262 | Immune response in chronic obstructive pulmonary disease | 3.5 | 42 | Citations (PDF) |
| 263 | Characteristics, stability and outcomes of the 2011 GOLD COPD groups in the ECLIPSE cohort | 8.7 | 173 | Citations (PDF) |
| 264 | Chronic Obstructive Pulmonary Disease and Risk of Lung Cancer: The Importance of Smoking and Timing of Diagnosis | 2.1 | 3 | Citations (PDF) |
| 265 | Is Aspirin Underused in Myocardial Infarction? | 3.6 | 2 | Citations (PDF) |
| 266 | Update in Chronic Obstructive Pulmonary Disease 2011 | 8.9 | 25 | Citations (PDF) |
| 267 | Abnormal Lung Aging in Chronic Obstructive Pulmonary Disease and Idiopathic Pulmonary Fibrosis | 8.9 | 242 | Citations (PDF) |
| 268 | Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study | 8.7 | 174 | Citations (PDF) |
| 269 | Association Between Treated and Untreated Obstructive Sleep Apnea and Risk of Hypertension | 16.5 | 681 | Citations (PDF) |
| 270 | Systemic Steroid Exposure Is Associated with Differential Methylation in Chronic Obstructive Pulmonary Disease | 8.9 | 76 | Citations (PDF) |
| 271 | Monitoring Breathing Rate at Home Allows Early Identification of COPD ExacerbationsChest, 2012, 142, 1524-1529 | 1.0 | 110 | Citations (PDF) |
| 272 | Chronic Obstructive Pulmonary Disease Phenotypes: Current Rather than Future Perspectives: Reply | 8.9 | 1 | Citations (PDF) |
| 273 | Genome-Wide Association Analysis of Blood Biomarkers in Chronic Obstructive Pulmonary Disease | 8.9 | 124 | Citations (PDF) |
| 274 | Bronchodilator responsiveness as a phenotypic characteristic of established chronic obstructive pulmonary disease | 5.6 | 177 | Citations (PDF) |
| 275 | The GOLD Initiative 2011: A Change of Paradigm? | 1.4 | 9 | Citations (PDF) |
| 276 | Predicting Outcomes from 6-Minute Walk Distance in Chronic Obstructive Pulmonary Disease | 2.4 | 221 | Citations (PDF) |
| 277 | Effect of Bronchial Colonisation on Airway and Systemic Inflammation in Stable COPD | 2.0 | 62 | Citations (PDF) |
| 278 | Inflammatory Biomarkers Improve Clinical Prediction of Mortality in Chronic Obstructive Pulmonary Disease | 8.9 | 402 | Citations (PDF) |
| 279 | Iniciativa GOLD 2011. ¿Cambio de paradigma? | 1.4 | 17 | Citations (PDF) |
| 280 | A genome-wide association study of COPD identifies a susceptibility locus on chromosome 19q13 | 2.9 | 229 | Citations (PDF) |
| 281 | An investigation of the resolution of inflammation (catabasis) in COPD | 4.2 | 23 | Citations (PDF) |
| 282 | Is The CAT Questionnaire Sensitive To Changes In Health Status In Patients With Severe COPD Exacerbations? | 2.0 | 78 | Citations (PDF) |
| 283 | Cigarette smoking behaviors and time since quitting are associated with differential DNA methylation across the human genome | 2.9 | 293 | Citations (PDF) |
| 284 | Site of Mitochondrial Reactive Oxygen Species Production in Skeletal Muscle of Chronic Obstructive Pulmonary Disease and Its Relationship with Exercise Oxidative Stress | 3.8 | 50 | Citations (PDF) |
| 285 | Variable DNA Methylation Is Associated with Chronic Obstructive Pulmonary Disease and Lung Function | 8.9 | 218 | Citations (PDF) |
| 286 | Persistent Systemic Inflammation is Associated with Poor Clinical Outcomes in COPD: A Novel Phenotype | 2.3 | 749 | Citations (PDF) |
| 287 | Clinical Audit of COPD Patients Requiring Hospital Admissions in Spain: AUDIPOC Study | 2.3 | 102 | Citations (PDF) |
| 288 | Systems medicine and integrated care to combat chronic noncommunicable diseases | 9.6 | 187 | Citations (PDF) |
| 289 | Current Controversies and Future Perspectives in Chronic Obstructive Pulmonary Disease | 8.9 | 102 | Citations (PDF) |
| 290 | P4 Medicine: the Future Around the Corner | 1.4 | 37 | Citations (PDF) |
| 291 | Molecular Mechanisms of Inflammation During Exacerbations of Chronic Obstructive Pulmonary Disease | 1.4 | 34 | Citations (PDF) |
| 292 | Medicina P4: el futuro a la vuelta de la esquina | 1.4 | 53 | Citations (PDF) |
| 293 | Mecanismos moleculares de inflamación durante las agudizaciones de la enfermedad pulmonar obstructiva crónica | 1.4 | 62 | Citations (PDF) |
| 294 | Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease | 4.2 | 77 | Citations (PDF) |
| 295 | Anti-Tissue Antibodies Are Related to Lung Function in Chronic Obstructive Pulmonary Disease | 8.9 | 103 | Citations (PDF) |
| 296 | Is Autoimmunity Really Related to the Pathogenesis of COPD? | 8.9 | 12 | Citations (PDF) |
| 297 | Night-time symptoms: a forgotten dimension of COPD | 8.2 | 221 | Citations (PDF) |
| 298 | The CIBERES Pulmonary Biobank Consortium: an opportunity for cooperative international respiratory research | 8.7 | 10 | Citations (PDF) |
| 299 | Identification and prospective validation of clinically relevant chronic obstructive pulmonary disease (COPD) subtypes | 5.6 | 285 | Citations (PDF) |
| 300 | Changes in Forced Expiratory Volume in 1 Second over Time in COPD | 34.5 | 902 | Citations (PDF) |
| 301 | Effects of exercise on mitochondrial DNA content in skeletal muscle of patients with COPD | 5.6 | 63 | Citations (PDF) |
| 302 | The influence of obesity and obstructive sleep apnea on metabolic hormones | 1.5 | 61 | Citations (PDF) |
| 303 | Impaired circadian variation of platelet activity in patients with sleep apnea | 1.5 | 26 | Citations (PDF) |
| 304 | α;1-Antitrypsin Protease Inhibitor MZ Heterozygosity Is Associated With Airflow Obstruction in Two Large CohortsChest, 2010, 138, 1125-1132 | 1.0 | 81 | Citations (PDF) |
| 305 | Abnormal Levels of Circulating Endothelial Progenitor Cells During Exacerbations of COPD | 2.6 | 42 | Citations (PDF) |
| 306 | Impacto de las nuevas opciones terapéuticas en la EPOC | 1.4 | 0 | Citations (PDF) |
| 307 | Introducción | 1.4 | 0 | Citations (PDF) |
| 308 | Fenotipos clínicos de la EPOC | 1.4 | 14 | Citations (PDF) |
| 309 | Characterisation of COPD heterogeneity in the ECLIPSE cohort | 4.2 | 1,045 | Citations (PDF) |
| 310 | Auditoria clínica de los pacientes hospitalizados por exacerbación de EPOC en España (estudio AUDIPOC): método y organización del trabajo | 1.4 | 31 | Citations (PDF) |
| 311 | Variability and effects of bronchial colonisation in patients with moderate COPD | 8.7 | 83 | Citations (PDF) |
| 312 | High Prevalence of Undiagnosed Airflow Limitation in Patients With Cardiovascular DiseaseChest, 2010, 137, 333-340 | 1.0 | 88 | Citations (PDF) |
| 313 | Multistudy Fine Mapping of Chromosome 2q Identifies
XRCC5
as a Chronic Obstructive Pulmonary Disease Susceptibility Gene | 8.9 | 29 | Citations (PDF) |
| 314 | Clinical Audit of Patients Admitted to Hospital in Spain due to Exacerbation of COPD (AUDIPOC Study): Method and Organisation | 1.4 | 23 | Citations (PDF) |
| 315 | Susceptibility to Exacerbation in Chronic Obstructive Pulmonary Disease | 34.5 | 2,689 | Citations (PDF) |
| 316 | Prognosis of COPD patients requiring frequent hospitalization: Role of airway infection | 2.6 | 33 | Citations (PDF) |
| 317 | Telomere shortening in sleep apnea syndrome | 2.6 | 72 | Citations (PDF) |
| 318 | Non-synonymous polymorphism in the neuropeptide S precursor gene and sleep apnea | 1.5 | 4 | Citations (PDF) |
| 319 | NontypeableHaemophilus influenzaeClearance by Alveolar Macrophages Is Impaired by Exposure to Cigarette Smoke | 2.7 | 125 | Citations (PDF) |
| 320 | Low-dose theophylline enhances the anti-inflammatory effects of steroids during exacerbations of COPD | 5.6 | 142 | Citations (PDF) |
| 321 | The Natural History of Chronic Airflow Obstruction Revisited | 8.9 | 609 | Citations (PDF) |
| 322 | Abnormal Transition Pore Kinetics and Cytochrome C Release in Muscle Mitochondria of Patients with Chronic Obstructive Pulmonary Disease | 3.8 | 45 | Citations (PDF) |
| 323 | Abnormal mitochondrial function in locomotor and respiratory muscles of COPD patients | 8.7 | 165 | Citations (PDF) |
| 324 | A controlled trial of noninvasive ventilation for chronic obstructive pulmonary disease exacerbations | 2.3 | 50 | Citations (PDF) |
| 325 | Actividad de una unidad de cuidados respiratorios intermedios dependiente de un servicio de neumología | 1.4 | 15 | Citations (PDF) |
| 326 | La heterogeneidad fenotípica de la EPOC | 1.4 | 28 | Citations (PDF) |
| 327 | EPOC e inflamación sistémica. Una vía de enlace para la comorbilidad | 1.4 | 6 | Citations (PDF) |
| 328 | CTLA4gene polymorphisms are associated with chronic bronchitis | 8.7 | 29 | Citations (PDF) |
| 329 | Prediction of risk of COPD exacerbations by the BODE index | 2.6 | 135 | Citations (PDF) |
| 330 | Characteristics of patients admitted for the first time for COPD exacerbation | 2.6 | 57 | Citations (PDF) |
| 331 | Immunologic Aspects of Chronic Obstructive Pulmonary Disease | 34.5 | 742 | Citations (PDF) |
| 332 | Activity of an Intermediate Respiratory Care Unit Attached to a Respiratory Medicine Department | 1.4 | 6 | Citations (PDF) |
| 333 | Effects of CPAP on oxidative stress and nitrate efficiency in sleep apnoea: a randomised trial | 5.6 | 170 | Citations (PDF) |
| 334 | Physical Activity and Clinical and Functional Status in COPD | 1.0 | 151 | Citations (PDF) |
| 335 | Investigating the Natural History of Lung FunctionChest, 2009, 135, 1330-1341 | 1.0 | 33 | Citations (PDF) |
| 336 | Sustained CTL activation by murine pulmonary epithelial cells promotes the development of COPD-like disease | 10.6 | 68 | Citations (PDF) |
| 337 | Impacto de la presencia de un neumólogo de guardia sobre la actividad de un servicio de neumología | 1.4 | 3 | Citations (PDF) |
| 338 | Impact of an On-duty Pulmonologist on the Activity of a Respiratory Medicine Department | 1.4 | 1 | Citations (PDF) |
| 339 | CIBER of Respiratory Diseases (CibeRes) | 1.4 | 7 | Citations (PDF) |
| 340 | COPD as a Systemic Disease | 2.0 | 234 | Citations (PDF) |
| 341 | Airway Wall Thickening and Emphysema Show Independent Familial Aggregation in Chronic Obstructive Pulmonary Disease | 8.9 | 288 | Citations (PDF) |
| 342 | Fluticasone propionate reduces bacterial airway epithelial invasion | 8.7 | 29 | Citations (PDF) |
| 343 | Impacto de la presencia de un neumólogo de guardia sobre la actividad de un servicio de neumología | 1.4 | 0 | Citations (PDF) |
| 344 | El CIBER de Enfermedades Respiratorias (CibeRes) | 1.4 | 0 | Citations (PDF) |
| 345 | Hipersonolência diurna e variáveis polissonográficas em doentes com síndroma de apneia do sono | 1.1 | 14 | Citations (PDF) |
| 346 | β3-Adrenergic receptor Trp64Arg polymorphism and increased body mass index in sleep apnoea | 8.7 | 19 | Citations (PDF) |
| 347 | Daytime sleepiness and polysomnographic variables in sleep apnoea patients | 8.7 | 206 | Citations (PDF) |
| 348 | Hipersonolência diurna e variáveis polissonográficas em doentes com síndroma de apneia do sono | 1.1 | 6 | Citations (PDF) |
| 349 | Reduced Expression of the Sarcoplasmic Calcium Pump SERCA2 in Skeletal Muscle From Patients With Chronic Obstructive Pulmonary Disease and Low Body Weight | 1.4 | 11 | Citations (PDF) |
| 350 | Disminución de la expresión de la bomba de calcio sarcoplásmica (SERCA2) en el músculo esquelético de pacientes con EPOC y bajo peso corporal | 1.4 | 5 | Citations (PDF) |
| 351 | Inflammatory proteins in patients with obstructive sleep apnea with and without daytime sleepiness | 1.5 | 93 | Citations (PDF) |
| 352 | Expression of Toll-like receptor 2 is up-regulated in monocytes from patients with chronic obstructive pulmonary disease | 4.2 | 74 | Citations (PDF) |
| 353 | Dynamic hyperinflation and pulmonary inflammation: a potentially relevant relationship?: FIGURE 1. | 8.2 | 17 | Citations (PDF) |
| 354 | The potential impact of anaemia of chronic disease in COPD | 8.7 | 154 | Citations (PDF) |
| 355 | Autoinmunidad en la EPOC | 1.4 | 5 | Citations (PDF) |
| 356 | Neuropeptide Y and Leptin in Patients with Obstructive Sleep Apnea Syndrome | 8.9 | 128 | Citations (PDF) |
| 357 | Systemic Effects of Chronic Obstructive Pulmonary Disease | 0.0 | 251 | Citations (PDF) |
| 358 | Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study | 62.1 | 4,371 | Citations (PDF) |
| 359 | Empleo de esteroides inhalados en el tratamiento de la EPOC | 0.1 | 0 | Citations (PDF) |
| 360 | Proposal for a multidimensional staging system for chronic obstructive pulmonary disease | 2.6 | 59 | Citations (PDF) |
| 361 | Read Me, Please! | 1.4 | 3 | Citations (PDF) |
| 362 | COPD at the 2004 9th European Pulmonary Summit | 2.3 | 2 | Citations (PDF) |
| 363 | Effects of obesity on C-reactive protein level and metabolic disturbances in male patients with obstructive sleep apnea | 2.0 | 124 | Citations (PDF) |
| 364 | Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper | 8.7 | 3,970 | Citations (PDF) |
| 365 | Expression of Adhesion Molecules During Apoptosis of Circulating Neutrophils in COPDChest, 2004, 125, 1837-1842 | 1.0 | 42 | Citations (PDF) |
| 366 | Nitric oxide synthase type I (nNOS), vascular endothelial growth factor (VEGF) and myoglobin-like expression in skeletal muscle of Antarctic icefishes (Notothenioidei: Channichthyidae) | 1.2 | 16 | Citations (PDF) |
| 367 | Long-term (72 hours) preservation of rat lungs | 2.5 | 4 | Citations (PDF) |
| 368 | Differential Response of Lymphocytes and Neutrophils to High Intensity Physical Activity and to Vitamin C Diet Supplementation | 2.6 | 46 | Citations (PDF) |
| 369 | Skeletal muscle changes in patients with obstructive sleep apnoea syndrome | 2.6 | 53 | Citations (PDF) |
| 370 | Skeletal Muscle Apoptosis and Weight Loss in Chronic Obstructive Pulmonary Disease | 8.9 | 315 | Citations (PDF) |
| 371 | Continuous Positive Airway Pressure in Patients without Daytime Sleepiness | 9.6 | 0 | Citations (PDF) |
| 372 | Disfunción muscular esquelética de la EPOC. Mecanismos celulares | 1.4 | 10 | Citations (PDF) |
| 373 | Chip genético (ADN array): el futuro ya está aquí | 1.4 | 5 | Citations (PDF) |
| 374 | The measurement of exhaled carbon monoxide is influenced by airflow obstruction | 8.7 | 31 | Citations (PDF) |
| 375 | Changes induced by oxygen in rat liver proteins identified by high-resolution two-dimensional gel electrophoresis | 0.2 | 6 | Citations (PDF) |
| 376 | Abnormal lipid peroxidation in patients with sleep apnoea | 8.7 | 233 | Citations (PDF) |
| 377 | The Activity of Cytochrome Oxidase Is Increased in Circulating Lymphocytes of Patients with Chronic Obstructive Pulmonary Disease, Asthma, and Chronic Arthritis | 8.9 | 113 | Citations (PDF) |
| 378 | Serial measurements of exhaled nitric oxide during exacerbations of chronic obstructive pulmonary disease | 8.7 | 116 | Citations (PDF) |
| 379 | Trends of prescribing patterns for the secondary prevention of myocardial infarction over a 13-year period | 2.0 | 20 | Citations (PDF) |
| 380 | Expression of Adhesion Molecules and G Proteins in Circulating Neutrophils in Chronic Obstructive Pulmonary Disease | 8.9 | 147 | Citations (PDF) |
| 381 | Cytochrome Oxidase Activity and Mitochondrial Gene Expression in Skeletal Muscle of Patients with Chronic Obstructive Pulmonary Disease | 8.9 | 129 | Citations (PDF) |
| 382 | Automobile Accidents in Patients with Sleep Apnea Syndrome: An Epidemiological and Mechanistic Study | 8.9 | 360 | Citations (PDF) |
| 383 | Beta-blockers and antithrombotic treatment for secondary prevention after acute myocardial infarction Towards an understanding of factors influencing clinical practice | 2.2 | 48 | Citations (PDF) |
| 384 | Structure and function relationships of the respiratory muscles | 8.7 | 33 | Citations (PDF) |
| 385 | Ventilation-Perfusion Mismatch in Patients with Pleural Effusion | 8.9 | 117 | Citations (PDF) |
| 386 | Noninvasive Ventilatory Support After Lung Resectional SurgeryChest, 1997, 112, 117-121 | 1.0 | 157 | Citations (PDF) |
| 387 | MECHANISMS OF GAS EXCHANGE IMPAIRMENT IN PATIENTS WITH LIVER CIRRHOSIS | 3.4 | 79 | Citations (PDF) |
| 388 | Long-term Effects of Nasal Intermittent Positive-Pressure Ventilation on Pulmonary Function and Sleep Architecture in Patients With Neuromuscular DiseasesChest, 1996, 110, 1179-1183 | 1.0 | 125 | Citations (PDF) |
| 389 | Clinical trials versus clinical practice in the secondary prevention of myocardial infarction | 2.0 | 21 | Citations (PDF) |
| 390 | Clinical and functional assessment of patients with idiopathic pulmonary fibrosis: results of a 3 year follow-up | 8.7 | 59 | Citations (PDF) |
| 391 | Sleep-related respiratory disturbances in patients with Duchenne muscular dystrophy | 8.7 | 139 | Citations (PDF) |
| 392 | Effect of pulmonary hypertension on gas exchange | 8.7 | 40 | Citations (PDF) |
| 393 | Secondary prophylaxis against myocardial infarction. | 0.1 | 0 | Citations (PDF) |
| 394 | Mechanisms of Abnormal Gas Exchange in Patients with Pneumonia | 2.2 | 63 | Citations (PDF) |
| 395 | Mechanisms of Gas-exchange Impairment in Idiopathic Pulmonary Fibrosis | 3.2 | 262 | Citations (PDF) |
| 396 | Ventilation-Perfusion Mismatch after Methacholine Challenge in Patients with Mild Bronchial Asthma | 3.2 | 59 | Citations (PDF) |
| 397 | Hypoxic Pulmonary Vasoconstriction and Gas Exchange During Exercise in Chronic Obstructive Pulmonary Disease | 1.0 | 147 | Citations (PDF) |
| 398 | Effects of Propranolol on Arterial Oxygenation and Oxygen Transport to Tissues in Patients with Cirrhosis | 3.2 | 45 | Citations (PDF) |
| 399 | The lung in patients with cirrhosis | 4.2 | 102 | Citations (PDF) |
| 400 | Puncion aspirativa transbronquial y lavado broncoalveolar en el diagnostico del cancer primitivo de pulmon | 1.4 | 3 | Citations (PDF) |
| 401 | Lung function in allogeneic bone marrow transplantation recipients | 8.7 | 13 | Citations (PDF) |
| 402 | Different patterns of gas exchange response to exercise in asbestosis and idiopathic pulmonary fibrosis | 8.7 | 64 | Citations (PDF) |
| 403 | Oxyhemoglobin affinity in patients with chronic obstructive pulmonary disease and acute respiratory failure | 0.5 | 30 | Citations (PDF) |
| 404 | Effect of Bronchial Colonisation on Airway and Systemic Inflammation in Stable COPD | 2.0 | 2 | Citations (PDF) |
| 405 | Reply to Thomson, to Neder
et al
., and to Wouters | 8.9 | 0 | Citations (PDF) |
| 406 | Molecular Interactions of SARS-CoV-2 in Lung Tissue of Patients with Chronic Obstructive Pulmonary Disease | 3.4 | 2 | Citations (PDF) |
| 407 | Chronic Obstructive Pulmonary Disease and Lung Cancer: A Review for Clinicians | 0.7 | 19 | Citations (PDF) |
| 408 | Reply to Guo
et al
. | 8.9 | 0 | Citations (PDF) |
| 409 | Effectiveness of Inhaler Devices in Adult Asthma and COPD | 0.1 | 15 | Citations (PDF) |
| 410 | Microbiological Monitoring in Therapeutic Trials in Chronic Obstructive Pulmonary Disease | 8.9 | 1 | Citations (PDF) |
| 411 | Treatment of chronic obstructive pulmonary disease: current pipeline and new opportunities | 79.7 | 18 | Citations (PDF) |
| 412 | The ROME COPD exacerbation proposal works! Time to move forward | 8.9 | 7 | Citations (PDF) |
| 413 | Treatable Traits. Why, What, How? | 2.6 | 8 | Citations (PDF) |
| 414 | Personalizing COPD care: Phenotypes, endotypes, GETomics, the trajectome, syndemics and treatable traits | 2.7 | 4 | Citations (PDF) |
| 415 | Lessons From the ANTES B+ Study | 1.4 | 1 | Citations (PDF) |
| 416 | Radiomic analysis of computed tomography scans in COPD patients relates to different clinical and biological features, and identifies different lung function trajectories during follow-up | 2.5 | 0 | Citations (PDF) |
| 417 | Addressing the Global Challenges of
COPD
and Asthma: A Shared Vision From the Global Initiative for Chronic Obstructive Pulmonary Disease (
GOLD
) and the Global Initiative for Asthma (
GINA
) | 4.0 | 2 | Citations (PDF) |
| 418 | COPD Management in Primary Care: Underutilisation of Nursing Consultations | 3.2 | 1 | Citations (PDF) |
| 419 | Joint statement from GOLD/GLI regarding the use of spirometry to define airflow obstruction and diagnose COPD | 8.7 | 1 | Citations (PDF) |
| 420 | Activation of the inflammasome pathway during exacerbations of COPD | 8.7 | 0 | Citations (PDF) |
| 421 | Peripheral neutrophil stiffness in severe COPD exacerbations | 8.7 | 0 | Citations (PDF) |
| 422 | Deployment of integrated care services for patients with long-term oxygen therapy (LTOT): Role of frailty | 8.7 | 0 | Citations (PDF) |
| 423 | Role of C reactive protein in non small cell lung cancer staging | 8.7 | 1 | Citations (PDF) |
| 424 | LSC 2011 Abstract: BAFF in the interaction between T regulatory and B cells in COPD | 8.7 | 0 | Citations (PDF) |
| 425 | The ATTAIN study: Bronchodilatory effect of aclidinium bromide in chronic obstructive pulmonary disease (COPD) | 8.7 | 0 | Citations (PDF) |
| 426 | Aclidinium bromide in patients with chronic obstructive pulmonary disease: Improvement in health status in ATTAIN | 8.7 | 0 | Citations (PDF) |
| 427 | Improvement in symptoms and rescue medication use with aclidinium bromide in patients with chronic obstructive pulmonary disease: Results from ATTAIN | 8.7 | 0 | Citations (PDF) |
| 428 | The relationship between persistent systemic inflammation and symptoms of depression among patients with COPD in the ECLIPSE cohort | 8.7 | 0 | Citations (PDF) |
| 429 | Expression of HLA-DR in circulating polymorphonuclear neutrophils of COPD patients | 8.7 | 0 | Citations (PDF) |
| 430 | In vivo characterization of COPD using endoscopic fibered confocal fluorescence microscopy | 8.7 | 0 | Citations (PDF) |
| 431 | FORWARD: A study of extrafine beclomethasone/formoterol compared with formoterol alone in patients with severe COPD and a history of exacerbations | 8.7 | 0 | Citations (PDF) |
| 432 | Endoplasmic reticulum stress in bronchial tissue in patients with COPD and lung cancer | 8.7 | 0 | Citations (PDF) |
| 433 | Pulmonary gas exchange in severe obesity: The effects of bariatric surgery | 8.7 | 0 | Citations (PDF) |
| 434 | Lung function tests in severe obese subjects before and one year after bariatric surgery | 8.7 | 0 | Citations (PDF) |
| 435 | Systemic inflammatory response to smoking in chronic obstructive pulmonary disease: Evidence of a gender effect | 8.7 | 0 | Citations (PDF) |
| 436 | Automatic alveolar ventilation-targeted NIV mode vs polysomnographic titration of fixed pressure in naive patients with chronic respiratory failure | 0.9 | 0 | Citations (PDF) |
| 437 | The EXACERBANTES Study (Exacerbation of Chronic Obstructive Pulmonary Disease According to the ANTES Proposal): Rationale, Goals and Design | 0.8 | 0 | Citations (PDF) |
| 438 | A GOLD Science Committee Perspective on Exacerbations and Cardiovascular Risk In COPD | 8.9 | 1 | Citations (PDF) |
| 439 | The Potential Role of DPP-1 Inhibitors in Chronic Obstructive Pulmonary Disease | 1.4 | 0 | Citations (PDF) |
| 440 | Transforming COPD by Addressing Two Key Bottlenecks: Diagnosis and Clinical Control During Follow-up | 1.4 | 0 | Citations (PDF) |
| 441 | Respiratory syncytial virus infection in COPD exacerbations: the RECODE study protocol | 1.9 | 0 | Citations (PDF) |
| 442 | Clarifying the GOLD 2026 guidance for initial pharmacological COPD treatment | 8.7 | 0 | Citations (PDF) |
